Emiltatug ledadotin (Emi-Le)

Name: Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: American hospital formulary service (AHFS), or other drug classification
Published: 2026-09-17T22:01:26-04:00

Adenoid cystic carcinoma with solid histology or high-grade transformation

Also known as XMT-1660

Manufacturer: Servier
Regulatory submission: Not announced
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

American hospital formulary service (AHFS), or other drug classification

1 evidence topic · 1 source

Mechanistic classification

“XMT-1660 is a site-specific DS DAR 6 ADC that induced complete tumor regressions in xenograft models of breast and ovarian cancer as well as in a syngeneic breast cancer model that is refractory to PD-1 immune checkpoint inhibition.” (opens the source at this quote in a new tab)

AHFS classification or ATC code

No evidence found.